Dean Li

President, Merck Research Laboratories
· tracked since Aug 2026
Calls
1
Win Rate
100.0%
return
+5.8%
Calls 1 1 Posts tracked · 0.3/day
Calls
7d 1
30d 1
90d 1
Best Calls
MRK Long +5.8%
Worst Calls
No live losers yet
Most Mentioned
MRK ×1
Recent Calls
MRK Long 2 days ago
Win Rate 100% Long 1 Short 0
Win Rate
7d —
30d —
90d —
Average Return +5.8% Long Return +5.8% Short Return -
Average Return
7d —
30d —
90d —
Loading charts...
Result
Result
Sort
Theme Stance
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
MRK Merck & ... Merck & Co., Inc.
Long
Aug 19
$145.00
+5.8%
Keytruda combo improves melanoma recurrence-free survival.
Dean Li says adding Moderna's personalized mRNA cancer treatment to Keytruda markedly reduces recurrence risk in high-risk melanoma, with Phase 2 durability out to five years, reinforcing Keytruda's immuno-oncology franchise and supporting a new combination treatment option.
Pharma & Biotech
YOUTUBE
Showing 1 of 1 calls · sorted by mentions

Dean Li has 1 trade ideas tracked on Buzzberg across 1 tickers since August 2026. Most covered: MRK.